New formulation of obesity drug tested in healthy volunteers
NCT ID NCT07221591
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 22 times
Summary
This study tests a new formulation of survodutide, a medicine being developed for obesity and liver conditions. About 100 healthy adults aged 18 to 65 with a BMI between 27 and 40 will receive either the current or new formulation once a week for about 6.5 months. Researchers will measure how much of the drug gets into the blood and monitor for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CRS Clinical Research Services Berlin GmbH
Berlin, 13627, Germany
-
CRS Clinical Research Services Mannheim GmbH
Mannheim, 68167, Germany
Conditions
Explore the condition pages connected to this study.